Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 0.41 |
| ▸ | CTRC | Q99895 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315997 | 1.00 | ELANE (0.41) | ELANECTRCBACE1MMP13PTGER3 | |
| SCHEMBL3850352 | 0.97 | MMP13 (0.41) | ELANECTRCBACE1MMP13PTGER3 | |
| SCHEMBL3850357 | 0.97 | MMP13 (0.41) | ELANECTRCBACE1MMP13PTGER3 | |
| SCHEMBL1328244 | 0.95 | ELANE (0.43) | ELANECTRCDRD2 | |
| SCHEMBL1328242 | 0.95 | ELANE (0.43) | ELANECTRCDRD2 | |
| SCHEMBL2319040 | 0.91 | PTGER3 (0.41) | ELANECTRCBACE1MMP13PTGER3 | |
| SCHEMBL2319046 | 0.91 | PTGER3 (0.41) | ELANECTRCBACE1MMP13PTGER3 | |
| SCHEMBL380513 | 0.89 | ELANE (0.40) | ELANECTRCBACE1 | |
| SCHEMBL381207 | 0.89 | ELANE (0.40) | ELANECTRCBACE1 | |
| SCHEMBL2314687 | 0.88 | PTGER3 (0.41) | ELANEBACE1MMP13PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | ELANE 2303/4885CTRC 4666/4885BACE1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.